42.60
-0.54 (-1.25%)
| 前收盘价格 | 43.14 |
| 收盘价格 | 41.80 |
| 成交量 | 1,669,141 |
| 平均成交量 (3个月) | 2,378,813 |
| 市值 | 5,328,152,064 |
| 价格/销量 (P/S) | 8.47 |
| 股市价格/股市净资产 (P/B) | 55.67 |
| 52周波幅 | |
| 利润日期 | 7 May 2025 - 12 May 2025 |
| 营业毛利率 | -74.02% |
| 营业利益率 (TTM) | -61.10% |
| 稀释每股收益 (EPS TTM) | -4.28 |
| 季度收入增长率 (YOY) | 33.90% |
| 流动比率 (MRQ) | 6.22 |
| 营业现金流 (OCF TTM) | -254.07 M |
| 杠杆自由现金流 (LFCF TTM) | -254.42 M |
| 资产报酬率 (ROA TTM) | -16.08% |
| 股东权益报酬率 (ROE TTM) | -609.28% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | Guardant Health, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.00 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.74% |
| 机构持股比例 | 98.21% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 60.00 (Barclays, 40.85%) | 购买 |
| 60.00 (Canaccord Genuity, 40.85%) | 购买 | |
| 中 | 55.00 (29.11%) | |
| 低 | 50.00 (Piper Sandler, 17.37%) | 购买 |
| 平均值 | 55.27 (29.74%) | |
| 总计 | 11 购买 | |
| 平均价格@调整类型 | 43.33 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stephens & Co. | 26 Mar 2025 | 55.00 (29.11%) | 购买 | 45.84 |
| Morgan Stanley | 06 Mar 2025 | 52.00 (22.07%) | 购买 | 40.17 |
| Piper Sandler | 26 Feb 2025 | 50.00 (17.37%) | 购买 | 43.19 |
| Canaccord Genuity | 24 Feb 2025 | 60.00 (40.85%) | 购买 | 42.44 |
| Guggenheim | 24 Feb 2025 | 56.00 (31.46%) | 购买 | 42.44 |
| Scotiabank | 24 Feb 2025 | 52.00 (22.07%) | 购买 | 42.44 |
| Goldman Sachs | 21 Feb 2025 | 56.00 (31.46%) | 购买 | 42.87 |
| 28 Jan 2025 | 49.00 (15.02%) | 购买 | 48.26 | |
| JP Morgan | 21 Feb 2025 | 55.00 (29.11%) | 购买 | 42.87 |
| Raymond James | 21 Feb 2025 | 59.00 (38.50%) | 购买 | 42.87 |
| Stifel | 21 Feb 2025 | 53.00 (24.41%) | 购买 | 42.87 |
| Barclays | 23 Jan 2025 | 60.00 (40.85%) | 购买 | 48.60 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合